Applied Therapeutics, Inc. (APLT)

Market Cap	47.14M
Revenue (ttm)	455,000
Net Income (ttm)	-105.62M
Shares Out	141.58M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,784,961
Open	0.3142
Previous Close	0.3038
Day's Range	0.3142 - 0.3448
52-Week Range	0.3000 - 10.6200
Beta	1.89
Analysts	Buy
Price Target	6.10 (+1,758.62%)
Earnings Date	Apr 14, 2025

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-C...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2019
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: APLT
• Website: https://www.appliedtherapeutics.com

Financial Performance

In 2024, Applied Therapeutics's revenue was $455,000, a decrease of -95.45% compared to the previous year's $9.99 million. Losses were -$105.62 million, -11.81% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for APLT stock is "Buy." The 12-month stock price forecast is $6.1, which is an increase of 1,758.62% from the latest price.

Price Target

$6.1

(1,758.62% upside)

Analyst Consensus: Buy